Shopping Cart
Remove All
Your shopping cart is currently empty
Sograzepide (Netazepide) is an orally active, selective and highly potent gastrin/CCK-B antagonist that inhibits gastrin/CCK-A activity and pappalysin 2 expression in type 1 gastric neuroendocrine tumors, and can induce regression of type 1 gastric neuroendocrine tumors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $99 | - | In Stock | |
| 5 mg | $249 | - | In Stock |
| Description | Sograzepide (Netazepide) is an orally active, selective and highly potent gastrin/CCK-B antagonist that inhibits gastrin/CCK-A activity and pappalysin 2 expression in type 1 gastric neuroendocrine tumors, and can induce regression of type 1 gastric neuroendocrine tumors. |
| Targets&IC50 | Gastrin/CCK-B:0.1 nM, Gastrin/CCK-A:501 nM |
| In vivo | Intravenous Sograzepide (0.1 μmol/kg) inhibited gastrin-induced gastric acid secretion in anesthetized rats at a dose of ED50 = 87 nM/kg. [1] At a dose of 10 μM/kg, Sograzepide showed inhibition of gastrin-induced gastric acid secretion with an ED50 = 0.0086 μM/kg, but had no effect on histamine- and bethanechol-induced gastric acid secretion. [2] |
| Synonyms | YM-220, YM220, YF476, YF 476, Netazepide |
| Molecular Weight | 498.58 |
| Formula | C28H30N6O3 |
| Cas No. | 155488-25-8 |
| Smiles | C(C(C(C)(C)C)=O)N1C=2C(C(=N[C@@H](NC(NC3=CC(NC)=CC=C3)=O)C1=O)C4=CC=CC=N4)=CC=CC2 |
| Relative Density. | 1.25 g/cm3 |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (160.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.62 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.